Novo Nordisk A/S
NONOFOTCHealthcare● Active
$41.25
$-2.11(-4.87%)
Market Cap$183.3B
P/E Ratio—
52W High$82.5
52W Low$34
Novo Nordisk A/S (NONOF) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NONOF · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $102.20B | $100.99B | $83.68B | $55.52B | $47.76B |
| Depreciation & Amort. | $14.63B | $8.54B | $9.41B | $7.36B | $6.03B |
| Stock-Based Comp. | $0.00B | $2.29B | $2.15B | $1.54B | $1.04B |
| Change in Working Capital | $3.73B | ($11.99B) | ($12.24B) | ($5.34B) | ($8.66B) |
| Net Cash from Operations | $118.83B | $120.97B | $108.91B | $78.89B | $55.00B |
| Investing Activities | |||||
| Capital Expenditure | ($60.00B) | ($51.31B) | ($38.90B) | ($14.75B) | ($7.38B) |
| Purchases of Investments | ($0.72B) | ($19.81B) | ($13.29B) | ($9.73B) | ($7.11B) |
| Sales of Investments | $10.65B | $24.39B | $8.29B | $6.64B | $1.17B |
| Net Cash from Investing | ($78.98B) | ($128.90B) | ($43.89B) | ($24.92B) | ($31.61B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($1.38B) | ($20.18B) | ($29.92B) | ($24.09B) | ($19.45B) |
| Dividends Paid | ($51.65B) | ($44.14B) | ($31.77B) | ($25.30B) | ($21.52B) |
| Debt Issued / Repaid | $26.19B | $73.06B | ($1.47B) | ($2.41B) | $15.47B |
| Net Cash from Financing | ($28.34B) | $8.73B | ($63.16B) | ($51.80B) | ($25.49B) |
| Free Cash Flow | |||||
| Free Cash Flow | $58.83B | $69.66B | $70.01B | $64.13B | $47.62B |
| FCF Margin %(computed) | 19.08% | 23.99% | 30.14% | 36.24% | 33.82% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · DKK · B
Explore more Novo Nordisk A/S data
About Novo Nordisk A/S (NONOF) Cash Flow Statement
Novo Nordisk A/S generated operating cash flow of $118.83B and free cash flow of $58.83B for 2025 — a FCF margin of 19.08%. Capital expenditure was ($60.00B).
Frequently asked questions
NONOF · 4 questionsNovo Nordisk A/S generated free cash flow of $58.83B for 2025, down 15.5% year-over-year.
NONOF free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10